Manufacturer of Fingolimod Hydrochloride - Lasofoxifene Tartrate CAS 190791-29-8 Chiral Purity ≥99.0% Purity ≥98.0% (HPLC) API High Purity – Ruifu
Manufacturer of Fingolimod Hydrochloride - Lasofoxifene Tartrate CAS 190791-29-8 Chiral Purity ≥99.0% Purity ≥98.0% (HPLC) API High Purity – Ruifu Detail:
Manufacturer Supply with High Purity and Stable Quality
Chemical Name: Lasofoxifene Tartrate
CAS: 190791-29-8
Appearance: White to Off-White Powder
Chiral Purity: ≥99.0% Purity: ≥98.0% (HPLC)
Lasofoxifene Tartrate (CAS: 190791-29-8) in the treatment of Postmenopausal Osteoporosis
| Chemical Name | Lasofoxifene Tartrate |
| Synonyms | (5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol Tartrate Oporia |
| CAS Number | 190791-29-8 |
| CAT Number | RF-API20 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C28H31NO2.ClH |
| Molecular Weight | 450.019 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Off-White Powder |
| Moisture (K.F) | ≤0.50% |
| Heavy Metals | ≤20ppm |
| Chiral Purity | ≥99.0% |
| Purity / Analysis Method | ≥98.0% (HPLC) |
| Loss on Drying | ≤0.50% |
| Residue on Ignition | ≤0.50% |
| Test Standard | Chinese Pharmacopoeia (CP); Enterprise Standard |
| Usage | Active Pharmaceutical Ingredient (API); Postmenopausal Osteoporosis |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer’s requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Lasofoxifene Tartrate (CAS: 190791-29-8) with high quality.
Lasofoxifene Tartrate is a third-generation, non-steroidal selective estrogen receptor modulator (SERM). It selectively binds to human ERalpha with an IC50 value of 1.5 nM and inhibits bone loss in ovariectomized rats. In clinical studies of postmenopausal osteoporosis, 0.5 mg/day lasofoxifene was associated with reduced risks of nonvertebral and vertebral fractures, ER-positive breast cancer, coronary heart disease, and stroke but an increased risk of venous thromboembolic events. Lasofoxifene has also been shown to act as an inverse agonist at the CB2 cannabinoid receptor, indicating its potential to be repurposed as a therapeutic for indications wherein CB2 is a target.
Product detail pictures:
Related Product Guide:
We have been experienced manufacturer. Wining the majority of your crucial certifications of its market for Manufacturer of Fingolimod Hydrochloride - Lasofoxifene Tartrate CAS 190791-29-8 Chiral Purity ≥99.0% Purity ≥98.0% (HPLC) API High Purity – Ruifu , The product will supply to all over the world, such as: Slovenia, Nairobi, Philippines, Our stock have valued 8 million dollar , you can find the competitive parts within short delivery time. Our company is not only your partner in business, but also our company is your assistant in the coming corporation.
By Alice from Czech Republic - 2017.11.11 11:41
As an international trading company, we have numerous partners, but about your company, I just want to say, you are really good, wide range, good quality, reasonable prices, warm and thoughtful service, advanced technology and equipment and workers have professional training, feedback and product update is timely, in short, this is a very pleasant cooperation, and we look forward to the next cooperation!
By Ellen from Puerto Rico - 2017.01.28 18:53